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1Department of Physics and Center for Biological Physics, Arizona State University, Tempe, ArizonaABSTRACT Determining the three-dimensional structure of myoglobin, the first solved structure of a protein, fundamentally
changed the way protein function was understood. Even more revolutionary was the information that came afterward: protein
dynamics play a critical role in biological functions. Therefore, understanding conformational dynamics is crucial to obtaining
a more complete picture of protein evolution. We recently analyzed the evolution of different protein families including green fluo-
rescent proteins (GFPs), b-lactamase inhibitors, and nuclear receptors, and we observed that the alteration of conformational
dynamics through allosteric regulation leads to functional changes. Moreover, proteome-wide conformational dynamics analysis
of more than 100 human proteins showed that mutations occurring at rigid residue positions are more susceptible to disease
than flexible residue positions. These studies suggest that disease-associated mutations may impair dynamic allosteric regula-
tions, leading to loss of function. Thus, in this study, we analyzed the conformational dynamics of the wild-type light chain subunit
of human ferritin protein along with the neutral and disease forms. We first performed replica exchange molecular dynamics sim-
ulations of wild-type and mutants to obtain equilibrated dynamics and then used perturbation response scanning (PRS), where
we introduced a random Brownian kick to a position and computed the fluctuation response of the chain using linear response
theory. Using this approach, we computed the dynamic flexibility index (DFI) for each position in the chain for the wild-type and
the mutants. DFI quantifies the resilience of a position to a perturbation and provides a flexibility/rigidity measurement for a given
position in the chain. The DFI analysis reveals that neutral variants and the wild-type exhibit similar flexibility profiles in which
experimentally determined functionally critical sites act as hinges in controlling the overall motion. However, disease mutations
alter the conformational dynamic profile, making hinges more loose (i.e., softening the hinges), thus impairing the allosterically
regulated dynamics.INTRODUCTIONProteins are the remarkable workhorses of life. In addition
to being proficient, specific, and diverse, proteins have the
paramount ability to evolve new functions. The ability to
evolve and adapt is remarkable considering all modern pro-
teins are thought to have diverged from a limited set of
ancestral proteins. Recent evolutionary events such as the
emergence of drug resistance and enzymes with the ability
to degrade antibiotics underscore the need to understand
the driving forces and mechanisms behind protein evolution.
In 1963, L. Pauling and E. Zuckerland stated it would be
possible one day to infer the gene sequences of ancestral
species to ‘‘synthesize these presumed components of
extinct organisms and study the physiochemical properties
of these molecules.’’ A half century later their prescient
vision has been realized through advances in computational
power, phylogenetics, and DNA synthesis. It is now possible
to obtain ancestral sequences and resurrect ancient gene
sequences in the laboratory. The first crucial step is to
generate accurate phylogenetic trees by methods such asSubmitted April 9, 2015, and accepted for publication June 30, 2015.
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0006-3495/15/09/1273/9parsimony (1,2), maximum likelihood (1,3–6), and Markov
Chain Monte Carlo-based Bayesian inference (7). These
studies have shown that, as function evolves, a protein’s
structure is more conserved than its sequence indicating
that conformational dynamics must play an integral role in
protein evolution.
Proteins are not static. A protein folded in its native
state in vivo has internal dynamics where some parts are
more flexible than others due to the interresidue network
of interactions. Protein dynamics is critical to biological
function—allosteric signaling, protein transport (8–12),
ligand recognition (13), electron transfer (14), enzymatic
reaction efficiency (15,16), and evolution of novel functions
(17). Furthermore, evolutionary sequence variability has
been analyzed in the context of protein structure dynamics
(18–23) and shows a high correlation between evolutionary
rates and the flexibility of individual positions (10,24).
Point mutations, either one or a few changes in the amino
acid sequence, can alter the flexibility of a protein, causing a
change in dynamics and, ultimately, the function. There is a
growing body of evidence to support the idea that biological
mechanisms can be explained by analyzing the contribution
of individual residues to the conformational dynamics and
stability of a protein (10,25–28).http://dx.doi.org/10.1016/j.bpj.2015.06.060
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evolves has recently been studied in three ancestral steroid
receptors, the ancestors of mineralocorticoid receptors
(MRs), and glucocorticoid receptors (GRs) (29). MRs and
GRs arose by duplication of a single ancestor (AncCR)
deep in the vertebrate lineage and then diverged in function.
Through structural comparison of human MR and GR, two
point mutations (S106P and L111Q) emerged to be critical
in ligand specificity. However, swapping these residues
between human MR and human GR yielded receptors
with no binding activity (30). By resurrecting key ancestral
proteins—AncCR, AncGR1, AncGR2—in MR and GR and
determining their crystal structures, Thornton and col-
leagues were able to shed insight into how function diverges
through time using both functional on-site and structural
off-site permissive mutations (31–33). AncCR and AncGR1
have a promiscuous binding affinity, AncGR2 exclusively
binds to cortisol. AncGR1 and AncGR2, which diverge
functionally through 36 mutations, have highly similar
experimental structures. However, a comparison of the con-
formational dynamics of the three ancestral proteins reveals
AncCR and AncGR1 have a flexible binding pocket,
suggesting flexibility plays a role in promiscuous binding
affinity. In contrast, the mutations of AncGR2 lead to a rigid
binding pocket, suggesting that as the binding pocket be-
comes cortisol specific, evolution acts to shape the binding
pocket toward a specific ligand. Critical mutations were
identified by analyzing the change in dynamics at each res-
idue position using the mean square fluctuation profile and
cross-correlation map.
Similar to the promiscuous ancestors of MRs and GRs,
proteins corresponding to 2- to 3-billion-year-old Precam-
brian nodes in the evolution of Class A b-lactamases have
been shown to be moderately efficient and promiscuous
catalysts that are able to degrade a variety of antibiotics
with catalytic efficiency levels similar to those of an average
enzyme (34). Promiscuity is thought to play an essential
role in the evolution of new functions as evinced by modern
enzymes (34), which are highly efficient specialists and
primordial enzymes, which were likely promiscuous gener-
alists. Modern-day proteins can be thought of as evolved
from generalists into specialists (35–40). Remarkably, there
are only a few structural differences—in particular at the
active-site regions—between the resurrected ancestral en-
zymes and penicillin-specialist modern b-lactamase. This
then raises the question whether the functional differences
arise from the conformational dynamics of the lactamases.
The dynamics of the lactamases were simulated using
replica exchange molecular dynamics (REMD). Then the
covariance matrix of C-alpha positions was calculated and
analyzed using perturbation response scanning (PRS)
(22,41). PRS relies on sequentially applying an external
random force (i.e., a Brownian kick) on a single residue
and quantifying the fluctuation response of other residues
(10,41,42) using linear response theory. In a crowded cellBiophysical Journal 109(6) 1273–1281environment, a protein can be exposed to many different
types of forces exerted by the surrounding macromolecules
and ligands. We mimic these forces, to a first approximation,
by applying small random forces on the protein and
computing the displacement of each residue through PRS
(22,41). PRS results, thus, allow us to calculate a metric
known as the dynamic flexibility index (DFI) that quantifies
the resilience of each given residue to a perturbation
occurring at another part of the chain (27) and quantifies
the flexible and rigid parts of a protein. The special
dynamics associated to substrate promiscuity of ancestral
b-lactamases was revealed by patterns of high DFI values
in regions close to the active site, illuminating the deform-
ability required for the binding and catalysis of different
ligands. These specific DFI patterns suggest that the pro-
tein’s native state is actually an ensemble of conformations
displaying the structural variability in the active site region
required for efficient binding of substrates of different sizes
and shapes. On the other hand, DFI analysis of modern
TEM-1 lactamase shows a comparatively rigid active-site
region, likely reflecting adaptation for the efficient degrada-
tion of a specific substrate, penicillin (43). Principal com-
ponent analysis of the ancestral b-lactamases and the
extant TEM-1 lactamase reveal the special dynamics associ-
ated with substrate promiscuity and is in agreement with the
functional divergence, as the highest-order modes of the
ancient b-lactamases cluster together, separated from their
modern descendant.
DFI analysis further reveals how functional evolution is
related to changes in flexibility, specifically at hinge points,
as the protein structure remains largely unchanged. Molec-
ular dynamics (MD) simulations and PRS of reconstructed
ancestral proteins of green fluorescent protein (GFP) shows
the evolution of red color from a green ancestor emerged by
migration of the hinge point from the active site diagonally
across the beta-barrel fold (44). Although the flexibility of
the mutational sites does not change in allosteric response
to these mutants, both an increase in flexibility (softening)
and decrease in flexibility (hardening) occurs for the regions
of the beta fold that are widely separated.
Although the reconstruction of ancestral proteins pro-
vides insights about evolution, genome sequencing provides
an opportunity to study protein evolution from a different
perspective. With advancements in genome sequencing
efforts, there has been an exponential growth in the
number of known nonsynonymous single nucleotide vari-
ants (nSNVs). It is now clear that each personal genome
contains millions of variants, many of which are nSNVs
(45). More importantly, variations in the human exome, pro-
tein coding region, are already associated with more than a
thousand diseases (46). Because disease-associated nSNVs
coded in exomes are the part of the human genome best
understood in how sequence relates to function via the
known phenotypic impact, they represent our best chance
to evaluate the role of conformational dynamics in genomics
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DFI metric was used to evaluate the effect of dynamic
flexibility of individual positions on biological fitness and
function in more than 100 proteins. The study found that
disease-associated mutations occur predominately at low
DFI sites (i.e., rigid hinge sites), indicating the importance
of hinge sites. Neutral mutations, however, were more abun-
dant at sites with high DFI, suggesting that flexible sites are
more robust to mutations (27,28).
In this study, we investigated whether the conformational
dynamics of a protein provides a mechanistic insight about
why certain mutations lead to disease whereas others do not,
even when both disease-associated and neutral mutations
are close in sequence and result in a severe biochemical
change upon mutation. Encouraged by the proteome-wide
results of DFI, we analyzed whether DFI can provide further
insight about disease mechanisms. We have studied the
wild-type light chain subunit of human ferritin protein
(FTL) and its mutant forms (Fig. 1). FTL contains 24 sub-
units and is able to store up to 4500 Fe (þ3 oxidation state)
atoms inside. Of these 24 subunits, some are of the heavy
form, which catalyze the oxidation of Fe2þ to Fe3þ with
oxygen, whereas the light form stores the oxidized iron
and regulates the release of Fe3þ via a gating mechanism.
The conformational dynamics of the light form subunit
were sampled using REMD on the wild-type and mutant
variants. DFI analysis was then performed to compare
the change in conformational dynamics between the wild-
type, neutral, and disease forms. As discussed in detail
below, DFI analysis provides a unique picture of a protein
as a machine controlled by rigid control knobs that transmit
information to flexible regions via allosteric residueFIGURE 1 (A) Human ferritin contains 24 subunits and can store up to
4500 ferric (þ3 oxidation state) atoms. Disruption in the function of ferritin
has been linked to iron misregulation, anemia, cataract syndrome, basal
ganglia disease, Hallervordern-Spatz Syndrome, Alzheimer’s disease, and
other neurodegenerative diseases. Of the 24 subunits, some are heavy
form, which catalyze the oxidation of Fe2þ to Fe3þ, whereas the light
form stores the oxidized form (PDB ID: 3AJO). (B) The light subunit of
the human ferritin protein colored from blue to red, where blue is the
N terminus and red is the C terminus. The important regions for its function
are the L1 loop (residues 40–50), critical for releasing Fe3þ and ion binding.
The other critical regions for ion binding sites are residues 57–64, 84–92,
and 118–135. (PDB ID: 2FG4). To see this figure in color, go online.communication. Thus, allosteric residue communication
between these rigid knobs and flexible portions is necessary
for function. We found that a mutation that impairs (softens)
these rigid knobs, leads to an overall loss in allosteric regu-
lation and uncontrolled flabby dynamics.MATERIALS AND METHODS
Human ferritin protein
The test set used for DFI analysis is the subunit of the FTL (PDB ID: 2FGL)
and its mutant forms—L23M, D42Y, T93P, H124R, T30I, R40G, A96T, and
H132P. The set of disease-associated mutations were found using the
Human Genome Mutation Database (47). Human ferritin is involved in
iron regulation; dysfunctions in the protein have been linked to disease-
associated nSNV(s) manifested through anemia, cataract syndrome (48),
basal ganglia disease (49,50), Parkinson’s disease (51), Huntington’s dis-
ease (52), Alzheimer’s disease, Hallverordern-Spatz syndrome (51–53),
and an array of other neurodegenerative diseases. FTL was chosen for its
integral role in human health and the experimental knowledge of disease-
associated and neutral nSNVs.REMD
The dynamics of the protein is sampled by running a REMD simulation.
REMD samples the dynamics of a protein by performing multiple simula-
tions at different temperatures (replicas) and allows the system to exchange
configurations between replicas (54). By simultaneously simulating the
protein at multiple temperatures, potential energy barriers that inhibit
sampling can be overcome. The REMD simulations for the wild-type and
mutants were simulated for 5 ns with convergence observed after 3 ns.
The replicas are exponentially distributed between 240K and 450K to opti-
mize the acceptance ratio for swapping structures (~0.5). The Amber99SB
force field (55) with generalized born surface area implicit solvent (56) is
used to perform the simulation. The covariance matrix is extracted for
the last half-nanosecond and used to calculate the DFI profile.PRS Method and DFI Analysis
The canonical PRS method is originally based on the elastic network model
(ENM), where the protein is viewed as an elastic network in which each
node represents a residue (C-alpha atom) and a harmonic interaction is
assigned to pairs of residues within a specified cutoff distance (22,41). In
PRS, an external random force (i.e., a Brownian-like kick) is sequentially
applied on each residue. The perturbation cascades through the residue
interaction network and may introduce conformational changes in the pro-
tein. The linear responses of other residues are formed as in the following:
½DR3Nx1 ¼ ½H13Nx3N½F3Nx1; (1)
where F is a unit random force on selected residues, H1 is the inverse of
the Hessian matrix, and DR is the positional displacements of the N resi-
dues of the protein in three dimensions.
However, an ENM-based PRS approach cannot capture the differences in
conformational dynamics caused by the changes in biochemical specificity
of mutated amino acids because it is a coarse-grained model lacking
biochemical detail. To compare the neutral and disease-associated variants
with similar backbone structures, we replace the ENM basis of PRS with
all-atom REMD simulations. Then after running equilibrated MD simula-
tions, we obtain the covariance matrix of the C-alpha positions. The inverse
of the Hessian matrix is replaced with the covariance matrix, G, derived
from the MD trajectory, i.e.,Biophysical Journal 109(6) 1273–1281
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Because MD simulations take into account long-range interactions, solva-
tion effects, and the biochemical specificity of amino acids, PRS using
the covariance matrix obtained from REMD leads to insight beyond the
scope of ENM-based PRS.
PRS quantifies the flexibility of a residue upon perturbation of other res-
idues using the DFI. To compute DFI, we first apply a unit random external
force on a single residue. The response vector of the positional displace-
ments, DR, is computed using Eq. 1. To ensure each perturbation is
isotropic, we perform the perturbation in ten different directions. The
perturbation is repeated for each residue and we obtain the following pertur-
bation matrix,A, which records the displacements for each residue upon the
perturbation of another residue:
½ANxN ¼
2
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where jDRjji ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
hðDRÞ2i
q
denotes the magnitude of the displacement by
residue i in response to the perturbation at residue j.
A given row of the perturbation matrix is the average displacement of a
specific residue from its equilibrium position when all other residues are
perturbed one at a time; a given column shows the response profile of all
residues under the perturbation of specific residue. DFI is defined as the
total displacement of residue i induced by perturbations placed on all
residues in the protein and is calculated by taking the sum of row i in the
matrix A (Eq. 3), which is normalized by the total displacement of all
residues as in the following:
DFIi ¼
PN
j¼ 1
jDRjji
PN
i¼ 1
PN
j¼ 1
jDRjji
: (4)
DFI is able to measure the impact of a nSNVon the structural dynamics of a
protein at a specific position. In evolutionary-based approaches, simplisticBiophysical Journal 109(6) 1273–1281measures that ignore dynamics such as the Grantham distance (57), a mea-
sure of the similarity of amino acid types by examining their side chain vol-
ume, polarity, and atomic composition, are frequently used.
To measure positions that are allosterically linked to functionally critical
hinge points through interresidue dynamics, we introduced the metric func-
tional-DFI (f-DFI). F-DFI is the ratio of the sum of the mean square fluctu-
ation response of the residue j upon functional site perturbations (i.e., active
or binding sites residues) to the response of residue j upon perturbations
on all residues. F-DFI enables us to identify residues that are more sensitive
to perturbations because of functionally critical residues. This index can be
crucial to finding functionally important residues that are sequentially and
spatially distant from the active or binding site, especially those involved in
allosteric regulation, and it is expressed as in the following:
f  DFIi ¼
PNfunctional
j¼Nfunctional
jDRjjiyNfunctional
PN
j¼ 1
PN
i¼ 1
jDRjjiyN
; (5)
where jDRj ji is the response fluctuation profile of residue j upon perturba-
tion of residue i. The numerator is the average mean square fluctuation
response obtained over the perturbation of the functionally critical residues
Nfunctional; the denominator is the average mean square fluctuation response
over all residues. Below we discuss the specific case of the FTL. When
computing the residues that are allosterically linked to regulatory loop
L1, Nfunctional is the total number of residues in the regulatory loop L1, Nfunc
tional-L1, (residues 40–50) and Nfunctional-Cterminus (residues 162–168) are the
residues of the C terminus.RESULTS AND DISCUSSION
We investigated whether protein conformational dynamics
can provide a mechanistic insight about why certain muta-
tions lead to disease whereas others do not, irrespective of
the fact that both types of mutations are very close in
sequence and represent severe biochemical changes (i.e.,
high Grantham distance). To this aim, we have chosen a
set of neutral (L23M, D42Y, T93P, and H124R) and disease
associated (T30I, R40G, A96T, and H132P) nSNVs that
have been observed in FTL (Fig. 2). Among those muta-
tions, T30I and R40G nSNVs are associated with cataractFIGURE 2 In addition to the wild-type of hu-
man ferritin we also studied the following neutral
and disease-associated mutation pairs respectively:
(A) H124R/H132P, (B) T93P/A96T, (C) L23M/
T30I, and (D) D42Y/R40G. T30I and R40G
mutations are associated with cataract syndrome.
A96T is associated with adult-onset basal ganglia
disease. H132P is associated with Parkinson’s dis-
ease. Each pair was chosen because it was close in
sequence, located in a secondary structure motif or
the integral L1 loop, and covering the biochemical
spectrum of amino acid mutations. Additionally,
these mutations have not been correctly predicted
as disease-associated mutations by other methods.
To see this figure in color, go online.
Dynamics and Allostery in Disease 1277syndrome (58,59). The A96T is associated with adult-onset
basal ganglia disease (60). The H132P mutation is associ-
ated with Parkinson’s disease (61). These mutations are spe-
cifically chosen for multiple reasons: 1) there are known
neutral nSNVs close in the sequence to the disease-associ-
ated nSNVs (e.g., L23M and T30I, R40G and D42Y, etc.);
2) the nSNVs occur in both secondary structural motifs
and a flexible loop region; and 3) the neutral and disease
variants span the biochemical spectrum for amino acids.
For instance, the disease variant R40G mutates arginine, a
positively charged amino acid, to glycine, the smallest
amino acid type that is also considered nonpolar in certain
scales. The neutral variant D42Y, which is close in sequence
to R40G, also has a drastic change from a negatively
charged amino acid to a hydrophobic amino acid.
Previous methods are unable to accurately predict these
mutations. Using FoldX (62) to calculate the DDG value,
the change in folding stability upon mutation, it would be
expected that disease variants should have larger DDG
values because they cause more destabilization. However,
comparison of the DDG values between disease and neutral
variants show only a marginal change in stability. These re-
sults are not surprising as previous studies indicate that
without at least limited backbone sampling, DDG values
are not accurate enough to distinguish disease versus neutral
nSNVs (63). In addition to the lack of prediction accuracy
via DDG values, disease prediction servers are unable to
accurately determine these mutations. Of the neutral
nSNVs, Polyphen-2 (64) correctly predicts L23M and
T93P mutations to be neutral, however, it fails in predicting
D42Y and H124R as disease-associated. Likewise for the
disease variants, Polyphen-2 incorrectly predicts the R40G
and A96T nSNV.
There is a growing body of evidence linking the signifi-
cant role of allosteric regulation in cellular function to dis-
ease and drug development in cases involving changes in
structure and dynamics of proteins (65,66). Moreover, the
mutations on the residue positions involved in allosteric
pathways between active and allosteric sites may impair
the function by disturbing allosteric communication, thus
leading to different populations of active and inactive con-
formations (65,67). Therefore we investigated the role of
structural dynamics on the phenotypic changes associated
with genotypic changes (nSNVs) by simulating the mono-
meric form of wild-type FTL structure along with the four
neutral and four diseases-associated mutations using
replica-exchange molecular dynamics. Our goal is to calcu-
late the dynamics profile of each position as they deviate
from unbound equilibrium, shedding light on the response
of specific residues to external forces experienced by the
protein. Therefore we use a PRS approach (see Materials
and Methods). In PRS, we introduce perturbations by
applying a random external unit force on single residues
as a first-order approximation to the forces exerted on a
protein in a crowded cell environment, then we analyzethe residue response fluctuation profile of the rest of the
chain using linear response theory. It has been shown that
PRS using an elastic network model or coupled with MD
can be useful to 1) obtain conformational changes upon
binding (22,41); 2) identify critical residues that mediate
long-range communication through dynamic allostery
(10,65,68–70); 3) predict a better binding affinity score
through rapidly generating an ensemble of configurations
for flexible docking (71–73); and 4) distinguish disease-
associated and putatively neutral population variations in
human proteome (27,28).
As defined, DFI is a relative value that indicates the
average fluctuation response at a specific residue site upon
perturbing the other residues one at a time. Sites with high
DFI are more flexible and prone to feel the perturbation of
other residues. Furthermore, because of this enhanced flex-
ibility, regions encompassing several high DFI residues are
expected to be more deformable overall. On the other hand,
sites with low DFI may absorb and transfer the perturbation
throughout the residue-dynamics communication network
in a cascade fashion. They are usually involved with hinge
parts of the protein that control the motion, similar to control
knobs in machines. After generating the covariance matrix
using REMD trajectories, we computed the DFI profiles
for each mutant along with the wild-type and obtained the
average DFI profile for disease and neutral mutants. Then
we subtracted the wild-type DFI from each nSNV DFI pro-
file to determine the change in DFI (DDFI) between mutant
and wild-type. The average DFI profiles of the neutral and
the disease-associated mutants are clearly distinct as shown
by the color-coded ribbon diagrams (Fig. 3). The positions
with low DFI are typically considered to be critical residues
that control motion, i.e., hinges; an increase in the DFI value
at these hinge points is interpreted as a loss of function.
Interestingly, the plot of DDFI profiles for disease and
neutral variants shows a distinct change in behavior at
the region of regulatory loop L1 (residues 4050) and the
C terminus a-helix, where the DFI values of the disease pro-
file are greatly increased relative to those of the neutral
variant. Strikingly, this agrees with experimental findings
that implicate the critical role of the C terminus and the
nearby (spatially) regulatory loop (L1) residues in disease
(53). Thus, an increase in DFI at these regions is correlated
with a loss in functionality.
Furthermore, we examine each disease-associated and
neutral nSNVs pair (close in sequence) to explore whether
alterations in a DFI profile can give a mechanistic insight
regarding how the disease develops. Cataract syndrome is
caused by both T30I and R40G variants, however, the two
neutral variants, close in sequence to these two disease-asso-
ciated mutations, L23M and D42Y, are benign. Fig. 4 A
shows that whereas both L23M and T30I disrupt the ion
binding region near region T130-T135, only the T30I
variant drastically increases the flexibility, increasing the
DFI values near the L1 loop and the C terminus a-helix.Biophysical Journal 109(6) 1273–1281
FIGURE 3 (Top) The ribbon diagrams of the wild-type, neutral, and dis-
ease-associated nSNVs colored by their average DFI value within a spec-
trum of blue to red with blue being the lowest (most rigid) and red being
the highest (most flexible). (Bottom) There is a significant increase in the
DFI profile of the disease form at the L1 loop (residues 40–50) and the
C-terminus. The ribbon diagram of the wild-type and disease forms corre-
spondingly show a major increase in the DFI profile of the L1 loop and
C-terminus. To see this figure in color, go online.
FIGURE 4 (A) The DFI profile for the wild-type (blue), L23M neutral
mutation (green), and the T30I disease mutation (red) with the correspond-
ing ribbon diagrams color-coded with respect to their DFI profiles, with
blue being the lowest (rigid) and red being the highest (flexible). The mu-
tations are shown in spherical representation on the ribbon diagram. The
DFI profile of T30I (red) is a signature of cataract syndrome with functional
disruptions near the L1 loop (residues 40–50) and the C terminus helix,
which is responsible for the gating mechanism. The increase in DFI leads
to a loss of function of those residues because of their inability to transmit
motion. (B) The DFI profile of the wild-type (blue), D42Y neutral mutation
(green), and R40G disease-associated mutation (red) with the correspond-
ing ribbon diagrams colored with respect to DFI profiles. The DFI profile of
R40G is nearly identical to the DFI profile of T30I. To see this figure in co-
lor, go online.
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tations in the L1 loop region (residues 4050) and near the
C terminus a-helix (74) to the disease. Thus, the increase in
the DFI at those regions is consistent with experimental
findings. Given that both T30I and R40G cause the same
disease, they could be expected to have similar DFI profiles.
Fig. 4 B shows that although the neutral D42Y nSNV
exhibits behavior similar to the wild-type, it does not signif-
icantly disrupt the DFI profile, whereas the R40G profile
is nearly identical to that of T30I, exhibiting the increase
in DFI in loop L1 and the C terminus. Another interesting
observation is that both disease-associated mutations are
far separated from the C terminus end of the protein,
yet they have an allosteric impact on the flexibility of
C terminus end.
All disease-associated nSNVs tested led to increased DFI
values around regulatory loop L1 and C terminus, as shown
in Fig. 3. Most of the mutations (Fig. 3) are not located in
those regions. The only special case is D42Y, which is
very close to loop L1. However, the neutral mutation
R40G is also in the same region of loop L1, and it does
not impair the function. The allosteric network disruption
by off-site nSNVs prompted us to investigate the role of
allosteric residues whose dynamics are coupled to achieve
functional regulation of FTL, because such coupling orches-
trates functional behaviors through the residue interaction
network of the given protein structure (9,71–73). For thisBiophysical Journal 109(6) 1273–1281analysis, we used the functional-DFI (f-DFI) metric for
identifying the residues exhibiting significant fluctuation re-
sponses upon perturbation of functionally important sites in
the protein (10). Thus, positions that are farther away from
the functional site exhibiting high f-DFI values are allosteric
sites, and dynamically linked to the functional sites. The
f-DFI profiles of the positions that are allosterically linked
to regulatory loop L1 were calculated for all the disease
and neutral nSNVs. The average f-DFI profile for the disease
and neutral mutations is obtained by taking the average over
all the disease and neutral variants respectively. Previous
DFI analysis showed that the L1 loop is a critical hinge
point (i.e., exhibiting low DFI values) in the wild-type,
and disease mutations cause an increase in DFI values in
this region, thus making this critical control knob softer.
In agreement with this picture, comparison of the neutral
and disease f-DFI profiles with that of the wild-type provide
a striking observation: the disease profile exhibits overall
higher f-DFI values than the wild-type (Fig. 5 A). The
FIGURE 5 The f-DFI profiles of the wild-type (blue), average neutral mutations (green), and average disease mutations (red). f-DFI measures the sensi-
tivity of each position (i.e., residue response fluctuation) to the functionally important residues, in this case (A) the L1 loop (residues 40–50) and (B) C ter-
minus involved in ion binding and the release of ions. f-DFI profiles of the disease mutations exhibit high overall values, suggesting the loss in allosteric
control of these functional regions. To see this figure in color, go online.
Dynamics and Allostery in Disease 1279high f-DFI profile suggests that losing rigidity in a function-
ally critical hinge region impairs the dynamic allosteric
residue coupling, leading to an overall flabby dysfunctional
protein. Similarly, when we repeated the f-DFI analysis for
the other critical hinge region, the C terminus, we observe
the same behavior. The disease f-DFI profile is, in general,
much greater suggesting the loss of dynamic allosteric
residue coupling as a possible commonly observable trait
for all disease-associated nSNVs (Fig. 5 B) as may also be
observed in somatic cancer mutations. Interestingly, in can-
cer distinguishing driver mutations from a preponderance
of neutral passenger mutations is a challenging task (75).
Moreover, more challenging cases occur with latent driver
mutations, which act a passengers; yet, these mutations
cooperatively drive disease with other emerging mutations
(67). Thus, metrics such as DFI and f-DFI analysis may
shed light on allosteric mechanisms these latent driver
mutations play in disease development.CONCLUSIONS
Earlier studies on reconstruction of ancestral proteins sug-
gest that nature uses changes in conformational dynamics
to evolve at the molecular level (17,29,33,43). Our recent
studies that incorporated the conformational dynamics of
hundreds of monomeric and multimeric proteins have
shown that protein dynamics has the power to distinguish
between disease-associated nSNVs that affect biological
function and neutral nSNVs that have no effect on function
at a proteome scale (27,28). This large-scale analysis
includes population variations implicated in diseases, func-
tionally critical positions (catalytic and binding sites),
and evolutionary rates of substitutions. It has produced
concordant patterns, indicating that preservation of dynamic
profiles of residues in a protein structure is crucial for main-
taining the biological function. Based on these findings, we
investigated how the dynamic profiles of residue positionsare different between disease and neutral variants. We stud-
ied the conformational dynamics of the wild-type FTL along
with four pairs of neutral and disease-associated variants. In
each case, the neutral and disease-associated nSNVs are
close in sequence and have a large biochemical change
upon mutation. Comparison of the dynamic profiles among
wild-type, disease, and neutral variants reveals that disease-
associated mutations soften the functionally critical regions
of human ferritin, leading to a flabby protein with loss of
allosterically regulated conformational dynamics.AUTHOR CONTRIBUTIONS
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